Abstract:Abstract Background Multiple sclerosis (MS) and neuromyelitis optica syndrome disease (NMOSD) are inflammatory diseases of the central nervous system. The pathogenesis and treatments for these two conditions are very different. Natural killer (NK) and natural killer T (NKT) cells are immune cells with an important role in shaping the immune response. B cells are involved in antigen presentation as well as antibody and cytokine production. There is conflicting evidence of the roles of NK, NKT, and B cells in the two conditions. We aimed to compare the frequency of CD3 − CD16 + CD56 + NK, CD3 + CD56 + NKT, and CD5 + CD19 + B cells in the peripheral blood and serum Interleukin-10 (IL-10) in patients with MS and NMOSD. Methods CD19 + CD5 + B, CD3 − CD16 + CD56 + NK, and CD3 + CD56 + NKT cells were quantitated by flow cytometry in 15 individuals with Interferon-Beta (IFN-β) treated relapsing–remitting MS (RRMS), 15 untreated RRMS, and 15 NMOSD patients as well as 30 healthy controls (HC). Serum IL-10 was measured using an enzyme-linked immunosorbent assay (ELISA). Results The percentage of CD3 − CD56 + CD16 + NK cells in the peripheral blood of IFN-treated MS (1.81 ± 0.87) was significantly lower than for untreated RRMS (4.74 ± 1.80), NMOSD (4.64 ± 1.26) and HC (5.83 ± 2.19) (p < 0.0001). There were also differences for the percentage of CD3 − CD16 + and CD3 − CD56 + cells (p < 0.001 and p < 0.0007; respectively). IFN-treated RRMS (2.89 ± 1.51) had the lowest proportion of CD3 + CD56 + among the study groups (p < 0.002). Untreated RRMS (5.56 ± 3.04) and NMOSD (5.47 ± 1.24) had higher levels of CD3 + CD56 + than the HC (3.16 ± 1.98). The mean percentage of CD19 + CD5 + B cells in the peripheral blood of untreated RRMS patients (1.32 ± 0.67) was higher compared to the patients with NMOSD (0.30 ± 0.20), HC (0.5 ± 0.22) and IFN-treated RRMS (0.81 ± 0.17) (p < 0.0001). Serum interleukin-10 was significantly higher in the IFN-treated RRMS (8.06 ± 5.39) and in HC (8.38 ± 2.84) compared to untreated RRMS (5.07 ± 1.44) and the patients with NMOSD (5.33 ± 2.56) (p < 0.003). Conclusions The lower proportion of CD3 − CD56 + CD16 + NK and CD3 + CD56 + cells in peripheral blood of IFN-treated RRMS compared to other groups suggests the importance of immunomodulation in patients with RRMS disorder. Based on the differences in CD19 + CD5 + B cells and serum IL-10 between patients and HC, supplementary assessments could be of value in clarifying their roles in autoimmunity.

[Different Responses of CD94/NKG2A-bright and CD94/NKG2A-dim NK Cell Subsets Isolated from Patients with Multiple Sclerosis to Interferon-Beta].

The frequencies of peripheral blood CD5+CD19+ B cells, CD3−CD16+CD56+ NK, and CD3+CD56+ NKT cells and serum interleukin-10 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder

Expansion of NK Cells by Engineered K562 Cells Co-Expressing 4-1BBL and Mmica, Combined with Soluble IL-21.

CD4+CD25+Foxp3+ Regulatory T Cells Suppress NKG2D-mediated NK Cell Cytotoxicity in Peripheral Blood.

Identification of Resting and Type I Ifn-Activated Human Nk Cell Mirnomes Reveals Microrna-378 and Microrna-30e As Negative Regulators of Nk Cell Cytotoxicity

Tumor-Induced Suppression of Interferon-Gamma Production and Enhancement of Interleukin-10 Production by Natural Killer (nk) Cells: Paralleled to Cd4(+) T Cells

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

Functionally Distinct Subsets of CD1d-restricted Natural Killer T Cells Revealed by CD1d Tetramer Staining

Opposing Effect of IFNγ and IFNα on Expression of NKG2 Receptors: Negative Regulation of IFNγ on NK Cells

Role for NKG2-A and NKG2-C surface receptors in chronic CD4+ T-cell responses

The Ratio of Circulating CD56dim NK Cells to Follicular T Helper Cells As a Promising Predictor for Disease Activity of Relapsing-Remitting Multiple Sclerosis

Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta and IL-10.

[Differences Between CD3⁺ TCRvα24⁺ NKT Cell and CD3⁺ TCRvβ11⁺ NKT Cell in PBMC].

[Differentiation of Natural Killer Cells into Two Functional Subsets: NKh1 and NKh2].

A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.

Distribution of Several Activating and Inhibitory Receptors on CD3−CD16+ NK Cells and Their Correlation with NK Cell Function in Healthy Individuals

Influence of In Vitro IL-2 or IL-15 Alone or in Combination with Hsp 70 Derived 14-Mer Peptide (TKD) on the Expression of NK Cell Activatory and Inhibitory Receptors on Peripheral Blood T Cells, B Cells and NKT Cells

The Differential Expression of Natural Killer Cells in NMOSD and MS

Effects of interferon on Natural Killer (NK) cells assessed by fluorescent probes and flow cytometry

IFN-β Induces the Proliferation of CD4+CD25+Foxp3+ Regulatory T Cells Through Upregulation of GITRL on Dendritic Cells in the Treatment of Multiple Sclerosis

[Expression and Function of Killer Immunologublin Receptor and CD57 of Natural Killer Cells].